NCT00053976View on ClinicalTrials.gov

Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

January 31, 2001

Primary Completion Date

November 30, 2003

Study Completion Date

November 30, 2004

Conditions
Graft Versus Host Disease
Interventions
BIOLOGICAL

Daclizumab

DRUG

methylprednisolone

DRUG

Placebo

Trial Locations (8)

10021

Memorial Sloan-Kettering Cancer Center, New York

55455

University of Minnesota Cancer Center, Minneapolis

75246

Baylor University Medical Center, Dallas

02114-2698

Massachusetts General Hospital, Boston

02115

Brigham and Women's Hospital, Boston

Dana Farber Cancer Institute, Boston

14263-0001

Roswell Park Cancer Institute, Buffalo

97239-3098

Cancer Institute at Oregon Health and Science University, Portland

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Dana-Farber Cancer Institute

OTHER

NCT00053976 - Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease | Biotech Hunter | Biotech Hunter